Company news
Precision Biosciences, Inc. (NASDAQ:DTIL) news
Precision Biosciences, Inc. news releases on 6ix. Latest, Aug 24, 2026: Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Press releases & updates
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
August 24, 2026
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6, 2026
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
July 31, 2026
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
July 27, 2026
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
June 29, 2026
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
May 27, 2026
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
May 21, 2026
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
April 30, 2026
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
April 29, 2026
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
April 28, 2026
Precision BioSciences Announces Grant of Inducement Awards under Nasdaq Listing Rule 5635(4)
April 27, 2026
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
April 22, 2026
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
April 14, 2026
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
March 11, 2026
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
March 10, 2026
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
March 10, 2026
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
March 8, 2026
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
March 2, 2026
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
February 18, 2026
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
February 11, 2026
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
January 12, 2026
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 23, 2025
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
November 19, 2025
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
November 10, 2025
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
November 10, 2025
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
November 3, 2025
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
October 31, 2025
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025
October 14, 2025
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases
October 9, 2025
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial
October 7, 2025
Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society
September 30, 2025
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
September 12, 2025
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
September 8, 2025
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
August 7, 2025
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
August 6, 2025
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
August 4, 2025
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
July 23, 2025
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
July 16, 2025
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
June 25, 2025
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 14, 2025
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
May 8, 2025
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
May 7, 2025
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 1, 2025
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
April 15, 2025
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 1, 2025
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
March 26, 2025
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
March 21, 2025